arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO

29 May 2014

Breda, The Netherlands / Ghent, Belgium – arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced hematological and solid tumors at the 50th annual meeting of the American Society of Clinical Oncology (ASCO; 30 May-3 June, 2014, Chicago, IL, USA).

arGEN-X reported in December 2013 that this study met its translational development goals: all pre-specified biological activity measures (e.g. target saturation, effector functions, immune-modulation) were met. The study also showed that ARGX-110 has a favorable safety profile and identified a dose that was advanced into a larger safety study in patients with a range of hematological and solid tumors. Patient recruitment into this expanded study began in January 2014 in Europe (ClinicalTrials.gov Identifier: NCT01813539) and top-line results are expected in 2015.

The results will be presented in a poster as follows:

**Poster Session:** Developmental Therapeutics - Immunotherapy

**Abstract number:** #3023

**Poster title:** A Phase 1, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematological malignancies.

**Date/time:**

- Monday 2 June, 1:15pm-4:15pm, Room S405
- Monday 2 June, 4:45pm-6:00pm, Room S406

**Presenter:** Ahmad Awada, Principal Investigator, Institut Jules Bordet

**Authors:** A. Awada¹, C. Rolfo², S. Rottey³, L. Ysebrant de Lendonck¹, W. Schroyens², F. Offner⁴, K. Silence⁴, T. Dreier⁴, M. Moshir⁴, H. de Haard⁴, M. Peeters², D. Bron¹, A. Thibault⁴, P. Aftimos¹.

¹Institut Jules Bordet, Université Libre de Bruxelles, Belgium;
²Universitair Ziekenhuis Antwerpen, Belgium; ³Universiteit Ziekenhuis Gent, Belgium; ⁴arGEN-X BVBA, Belgium.
### About ARGX-110

ARGX-110 is a first-in-class monoclonal antibody that potently blocks CD70-induced tumor proliferation and tumor escape from immune surveillance. In addition, the POTELLIGENT®-enhanced antibody-dependent cellular cytotoxicity (ADCC) of ARGX-110 enables selective destruction of CD70-positive tumor cells. CD70 is overexpressed in the majority of cancer patients tested to date. Expectations of a favourable therapeutic index stem from its virtual absence in healthy tissues.

### About the ARGX-110 Study

The Phase 1 study (ClinicalTrials.gov Identifier: NCT01813539) consists of a dose-escalation phase followed by an adaptive safety study conducted in patients with advanced, refractory cancer. The patient enrichment strategy relies on individual tumor screening for CD70 utilizing a reproducible immunohistochemistry method. In addition to traditional clinical and PK/PD endpoints, biomarkers documenting the three modes of action of ARGX-110 are being evaluated. Patient enrolment is planned at approximately 90 CD70-positive patients with either hematological or solid tumors. The study is managed jointly by arGEN-X and a consortium of leading academic institutions in Belgium and France.

### About arGEN-X

arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. arGEN-X has generated a clinical pipeline of differentiated antibody candidates using its SIMPLE Antibody™ discovery platform. SIMPLE Antibody™ has a particular strength in addressing novel, complex disease targets that are difficult to access using established antibody technology platforms. Fc engineering technologies – NHance®, ABDEG™ and POTELLIGENT® – further enhance the therapeutic properties of SIMPLE Antibody™ leads in terms of their residence time in the body, their ability to clear disease targets or pathogenic antibodies and their cell killing potency through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged its suite of antibody technologies in forging strategic collaborations with pharmaceutical and biotechnology companies to provide new approaches to diseases with unmet medical needs.

[www.arGEN-X.com](http://www.arGEN-X.com)